[Personalized therapy concepts for malignant melanoma]

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Context:

• Metastatic melanoma remains a challenging cancer with limited effective systemic therapies prior to 2011.
• Cytotoxic chemotherapy offered limited response rates in a small patient subgroup.
• Advances in understanding melanoma's molecular pathology have identified key mutations for targeted treatment.

Purpose:

• To review the advancements in systemic therapy for metastatic melanoma.
• To highlight the impact of molecular profiling and immunotherapy on treatment strategies.
• To discuss novel therapeutic targets and their clinical implications.

Summary:

• Activating mutations in the BRAF gene, found in approximately 50% of melanomas, are targets for specific inhibitors.
• Mutations in c-Kit and NRAS also present opportunities for targeted therapies.
• Immunotherapy, including CTLA-4 blockade and PD-1/PD-L1 targeting, activates cytotoxic T cells to combat melanoma.

Impact:

• For the first time, life-prolonging systemic therapies are available for metastatic melanoma patients.
• Targeted therapies and immunotherapy represent a paradigm shift in melanoma treatment.
• These advancements offer improved survival outcomes and new hope for patients with advanced melanoma.